PapersPMID:27560482
Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
What moved
1 findingHow to read these marks →- Increases total cholesterol (TC)
moderate
“As shown in, total cholesterol (MD = 0.49, 95% CI: 0.18, 0.80, P < 0.05) and LDL (MD = 0.47, 95% CI: 0.21, 0.74, P < 0.05) levels were significantly higher in subjects supplemented with resveratrol than control subjects.”
- Study
- meta-analysis
- Effect
- 0.49 mean difference, 95% CI 0.18 to 0.8
- Dose studied
- 500-3000 mg/day resveratrol
- Population
- Adults with non-alcoholic fatty liver disease; total cholesterol pooled from 3 of the 4 placebo-controlled trials
Study record
- Design
- meta-analysis
- Species
- human
- Population
- adults with non-alcoholic fatty liver disease
- Participants
- 156
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 15
resveratrol